Further investigation is necessary to clarify the precise mechanisms among GH, IGF-1and NAFLD, and whether or not long-term GH treatment can improve the NAFLD and the specific dose of GH also needs to be determined by further studies with larger samples. This evidence concerns the gene GH1 and metabolic dysfunction-associated steatotic liver disease.